Aravive (NASDAQ:ARAV) has received a Buy recommendation from HC Wainwright & Co., as per Fintel reports on May 25, 2023. The average price target for Aravive as of May 11, 2023 is 13.26, representing an increase of 802.04% from its latest reported closing price of 1.47.
Aravive is a clinical-stage oncology company that develops therapeutics to treat life-threatening diseases. Its lead product candidate, AVB-500, is an ultra-high affinity decoy protein used to target tumor cell growth associated with the GAS6-AXL signaling pathway. The company has initiated a registrational Phase 3 trial of AVB-500 at a dose of 15 mg/kg after successfully completing a safety trial of the same in platinum resistant ovarian cancer.
As of the last quarter, 59 funds or institutions have reported positions in Aravive, an increase of 5 owners or 9.26%. Bvf, Artal Group, and Baker Bros. Advisors hold the highest number of shares representing 7.99%, 7.64%, and 5.45% ownership, respectively.
The average projected annual revenue for Aravive is 1MM, with the average predicted EPS estimated at -1.37. The put/call ratio of ARAV is 1.89, indicating a bearish outlook.
This article was originally published on Fintel.
Disclaimer: The views and opinions expressed in this article belong to the author and do not necessarily represent those of Nasdaq, Inc.
